How did GSK obtain a declination?
If GlaxoSmithKline deserved a declination to prosecute, then the Justice Department needs to provide a better explanation as to why. Tom Fox reports.
THIS IS MEMBERS-ONLY CONTENT
You are not logged in and do not have access to members-only content.
If you are already a registered user or a member, SIGN IN now.
Related articles
-
PremiumUnder intense pressure, former DOJ Polite says it’s compliance’s time to shine
Like never before in modern American history, ethics and compliance are under attack.
-
PremiumGlencore compliance monitorships ended early by DOJ
The U.S. Department of Justice ended two compliance monitorships on Glencore International more than a year early, monitorships imposed in 2022 after the company was convicted of paying bribes and manipulating commodities markets.
-
PremiumTrump family buys into crypto as regulators consider soft touch on the industry
Any doubts that the new administration will take a light touch to upcoming cryptocurrency regulation vanished with President Donald Trump’s launch of his own stablecoin and his family’s growing investments in crypto businesses.